期刊文献+

阿尔茨海默病的调节性T细胞功能检测 被引量:1

T cells regulatory function in Alzheimer's Disease
下载PDF
导出
摘要 目的对阿尔茨海默病(AD)患者外周血调节性T细胞功能进行研究。方法流式细胞仪测定T细胞亚群;细胞分选仪分离调节性T细胞,体外培养行淋巴细胞混合培养法检测调节性T细胞对同源/异源淋巴细胞增殖的抑制效应;ELISA法检测调节性T细胞细胞因子肿瘤坏死因子-β、白细胞介素-10的分泌水平。结果CD4+CD25+调节性T细胞细胞比例和健康对照组相比差异无显著性。肿瘤坏死因子-β、白细胞介素-10的分泌2组间差异无显著性。AD组调节性T细胞抑制功能受损,与对照组有明显差异。结论AD患者调节性T细胞抑制功能受损,可能与其接触抑制途径缺陷有关。 Objective To investigate the suppressive function of T regulatory cell in Alzheimer's disease ( AD ) patients. Methods The T lymphocyte subset was detected by flow cytometery. The CD4 ^+ CD25 hi T regulatory cells were purified by eell sorter. The secretion of TNF-β, and IL-10 were measured by ELISA. The direct suppression effect of CD4 ^+ CD25hi T regulatory cells on T lymphoeytes proliferation were performed by the mixed lymphoeytes reaction and measured by 3H-Thymidine radioactive assay. Results No significant differences were found in T lymphocyte subpopulations, including CD4 ^+ CD25hi T regulatory cells between groups. No significant differences were found in TNFβ, and IL-10 secretion. A significant decrease was found in the function of CD4 ^+ CD25 hi T regulatory cells from peripheral blood of patients with AD as compared with healthy donors ( P 〈 0.05 ). Conclusion The decreased suppressive effect may be related with the deficit in the pathway of cell-to-cell contact.
出处 《中国医药》 2006年第8期459-461,共3页 China Medicine
关键词 阿尔茨海默病 调节性T细胞 混合淋巴细胞反应 Alzheimer disease T regulatory cell Mixed lymphocytes reaction
  • 相关文献

参考文献11

  • 1曾赤佳,孟霞,胡河.阿尔茨海默病患者淀粉样β蛋白和肿瘤坏死因子测定的临床意义[J].中国基层医药,2004,11(12):1461-1462. 被引量:6
  • 2Trieb K;Ransmayr G;Sgonc R.APP peptides stimulate lymphocyte proliferation in normals,but not in patients with Alzheimer's disease[J],1996(05).
  • 3Hori S;Nomura T;Sakaguchi S.Control of regulatory T cell development by the transcription factor Foxp3[J],2003(5609).
  • 4Jonuleit HE;Schmitt K;Steinbrink AH.Dendritic cells as a tool to induce anergic and regulatory T cells[J],2001(07).
  • 5Jonuleit H;Schmitt E;Schuler G.Induction of interleukin 10-producing,nonproliferating CD4 + T cells with regulatory properties by repetitive stimulation with allogenic immature human dendritic cells[J],2000(04).
  • 6Schenk D;Barbour R;Dunn W.Immunization with amyloidbeta attenuates Alzheimer-disease-like pathology in the PDAPP mouse[J],1999(02).
  • 7徐武华,东海林干夫,松原悦朗.阿尔茨海默病患者自身抗β淀粉样蛋白抗体的免疫特性和临床价值[J].中华老年医学杂志,2006,25(2):89-92. 被引量:5
  • 8Yu P;Gregg RK;Bell JJ.Specific T Regulatory Cells Display Broad Suppressive Functions against Experimental Allergic Encephalomyelitis upon Activation with Cognate Antigen[J],2005(11).
  • 9Gelinas DS;DaSilva K;Fenili D.Immunotherapy for Alzheimer's disease[J],2004(z2).
  • 10Greenberg SM;Bacskai B J;Hyman BT.Alzheimer disease's double-edged vaccine[J],2003(04).

二级参考文献16

  • 1Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002,297 : 353-356.
  • 2Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 1999, 400:173-177.
  • 3Nicoll JA, Wilkinson D, Holmes C, et al.Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptlde: a case report.Nat Med,2003, 9:448-452.
  • 4Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron, 2003, 38:547-554.
  • 5Du Y, Dodel R, Hampel H, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease.Neurology, 2001, 57 : 801-805.
  • 6Nath A, Hall E, Tuzova M, et al. Autoantibodies to amyloid beta-peptide ( Abeta ) are increased in AlzheimerPs disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med, 2003,3:29-39.
  • 7Hyman BT, Smith C, Buldyrev I, et al.Autoantibodies to amyloid-beta and Alzheimer' s disease. Ann Neurol, 2001, 49:808-810.
  • 8McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer' s disease., report of the NINCDS-ADRDA Work Group under the auspices of department of Health and Human Services Task Force on Alzheimer' s Disease. Neurology, 1984, 34:939-944.
  • 9Harigaya Y, Shoji M, Kawarabayashi, T, et al.Modified amyloid 13 protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease. Biochem Biophysic Res Comm,1995,211 : 1015-1022.
  • 10Hock C, Konietzko U, Papassotiropoulos A, et al.Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med, 2002,8:1270-1275.

共引文献10

同被引文献2

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部